Tarsus Pharmaceuticals

TARS56

$32.55arrow_drop_up4.83%$1.50

TARS56

$32.55

arrow_drop_up4.83%$1.50

Performance History

Key Stats
Open	$31.15
Prev. Close	$31.06
EPS	-4.46
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	31.05	32.32
52 Week Range	12.57	42.50

Ratios







EPS	-4.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc (TARS) is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with ophthalmic diseases. With a strong emphasis on research and development, Tarsus is working to address unmet medical needs in the eye care space. The company's mission is to improve and preserve vision for individuals who suffer from various eye conditions.

As of the most recent quote, Tarsus Pharmaceuticals Inc (TARS) stock price sits at $XX.XX per share. The company's stock has shown consistent growth over the years, which can be attributed to its promising pipeline of potential treatments. Investors have shown interest in Tarsus due to its dedication to advancing ophthalmic therapies and its potential for long-term financial success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Bobak R. Azamian M.D.
Headquarters: Irvine
Employees: 87
Exchange: NASDAQ

Keep an eye on Tarsus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Tarsus Pharmaceuticals 's (TARS) price per share?

The current price per share for Tarsus Pharmaceuticals (TARS) is $32.55. The stock has seen a price change of $1.5 recently, indicating a 4.83% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Tarsus Pharmaceuticals (TARS)?

For Tarsus Pharmaceuticals (TARS), the 52-week high is $42.5, which is 30.57% from the current price. The 52-week low is $12.57, the current price is 158.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Tarsus Pharmaceuticals (TARS) a growth stock?

Tarsus Pharmaceuticals (TARS) has shown an average price growth of 0.41% over the past three years. It has received a score of 82 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Tarsus Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Tarsus Pharmaceuticals (TARS) stock price performance year to date (YTD)?

As of the latest data, Tarsus Pharmaceuticals (TARS) has a year-to-date price change of 61.46%. Over the past month, the stock has experienced a price change of 22.78%. Over the last three months, the change has been 12.86%. Over the past six months, the figure is 6.34%.

help

Is Tarsus Pharmaceuticals (TARS) a profitable company?

Tarsus Pharmaceuticals (TARS) has a net income of -$135.89M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 90.87% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -81.6% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $17.45M, although specific revenue growth data is currently not available. The gross profit is $15.85M. Operating income is noted at -$143.16M. Furthermore, the EBITDA is -$155.27M.

help

What is the market capitalization of Tarsus Pharmaceuticals (TARS)?

Tarsus Pharmaceuticals (TARS) has a market capitalization of $1.21B. The average daily trading volume is 752.6K, indicating the stock's liquidity and investor engagement.